Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Metastasis Rev. 2006 Dec;25(4):707-13.

Anti-angiogenic therapy for osteosarcoma.

Author information

  • 1Department of Orthopaedics, University of Melbourne, St. Vincent's Hospital Melbourne, P O Box 2900, Fitzroy 3065, Australia.

Abstract

Even in tumor centers using established protocols, the survival rate of patients with osteosarcoma has not improved significantly in recent years. Novel therapies are urgently needed as an adjunct to conventional treatment modalities, to reduce the dose and subsequent toxicity associated with current chemotherapy, improve local disease control, prevent development of metastases, and offer an alternative treatment for those tumors that are poorly responsive to chemotherapy. Anti-angiogenic therapy currently holds great potential in conjunction with conventional treatment modalities for osteosarcoma. Specifically, anti-angiogenic factors derived from cartilage, a natural barrier to osteosarcoma invasion, may have important therapeutic applications in osteosarcoma.

PMID:
17160710
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk